Avadel Pharmaceuticals plc

(NASDAQ:AVDL)

Latest On Avadel Pharmaceuticals plc (AVDL):

Date/Time Type Description Signal Details
2023-05-17 12:48 ESTNewsAvadel Pharmaceuticals: Lumryz Approved, Launch Expected June 2023 And We Remain BullishN/A
2023-05-04 21:04 ESTNewsAvadel Pharmaceuticals GAAP EPS of -$0.48 misses by $0.10N/A
2023-05-03 19:46 ESTNewsAvadel Pharmaceuticals' Strategic Moves To Conquer The Narcolepsy Market (Rating Upgrade)N/A
2023-05-01 18:02 ESTNewsAvadel gains 12% as FDA issues final approval for sleep therapyN/A
2023-04-19 19:06 ESTNewsAvadel: Sleeping Soundly, Why We're Giving A 'Buy' Rating Ahead Of Lumryz LaunchN/A
2023-04-01 06:51 ESTNewsAvadel Pharmaceuticals plc (AVDL) Q4 2022 Earnings Call TranscriptN/A
2023-03-30 23:36 ESTNewsAvadel Pharmaceuticals prices ADSs and Series B preferred shares offeringN/A
2023-03-30 23:36 ESTNewsAvadel Pharmaceuticals GAAP EPS of -$0.44 misses by $0.17N/A
2023-03-29 23:23 ESTNewsAvadel Pharma enters into royalty agreement with RTW investments for up to $75MN/A
2023-03-22 22:21 ESTNewsAvadel stock rises on FDA nod to import sleep disorder drug Lumryz ahead of potential approvalN/A
2023-03-12 15:40 ESTNewsAvadel Pharmaceuticals: Real-World Data Supports Market Opportunity For LumryzN/A
2023-03-07 14:48 ESTNewsNavigating Avadel's Potential And Risks With LumryzN/A
2023-03-02 11:50 ESTNewsAvadel requests final FDA approval for Lumyrz in narcolepsyN/A
2023-03-02 11:50 ESTNewsSenators introduce legislation to eliminate drug company loophole that delays competitionN/A
2023-02-25 02:43 ESTNewsAvadel seeks full FDA approval for sleep therapy as Jazz loses patent appealN/A
2022-12-09 12:50 ESTNewsAvadel And Jazz: The Oxybate Wars - Duking It OutN/A
2022-12-07 06:29 ESTNewsAvadel: Lumryz Overhang Now Removed, Rate BuyN/A
2022-11-30 11:51 ESTNewsAvadel surges 13% as Jefferies upgrades on opportunity to dent Jazz's market shareN/A
2022-11-19 02:02 ESTNewsAvadel Pharmaceuticals jumps on patent win in dispute with Jazz Pharma (update)N/A
2022-11-11 23:25 ESTNewsAvadel at eight-month high as FTC comments raise prospects for lead drugN/A
2022-11-09 18:40 ESTNewsAvadel Pharmaceuticals GAAP EPS of -$0.33 misses by $0.07N/A
2022-11-09 18:40 ESTNewsAvadel Pharmaceuticals plc (AVDL) Q3 2022 Earnings Call TranscriptN/A
2022-10-05 16:44 ESTNewsENPH, ATHX and AVDL among mid-day moversN/A
2022-09-06 20:37 ESTNewsAvadel's LUMRYZ: A Good Night's Sleep For Narcolepsy PatientsN/A
2022-09-05 11:33 ESTNewsAvadel Pharmaceuticals: Navigating Through The UncertaintyN/A
2022-09-01 00:30 ESTNewsAvadel Pharmaceuticals filed for 500M mixed shelf offeringN/A
2022-08-25 23:39 ESTNewsAvadel gains as judge delays hearing on patent dispute with Jazz PharmaN/A
2022-08-10 10:51 ESTNewsAvadel Pharmaceuticals plc (AVDL) CEO Gregory Divis on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-09 16:29 ESTNewsAvadel Pharmaceuticals GAAP EPS of -$1.07 misses by $0.66N/A
2022-08-08 16:19 ESTNewsAvadel Pharmaceuticals Q2 2022 Earnings PreviewN/A
2022-07-19 12:00 ESTNewsAvadel stock rises 8% as FDA grants tentative approval to its Jazz's sleep disorder drug rivalN/A
2022-06-30 04:47 ESTNewsAvadel rises 18% as it expects tentative approval for sleep disorder drug; expects final approval by June 2023N/A
2022-06-17 06:54 ESTNewsAvadel: Further Delay, But Some Light At The End Of The TunnelN/A
2022-06-02 01:57 ESTNewsAvadel Pharmaceuticals reports insider transactions from Director, CEO & CFON/A
2022-05-27 14:51 ESTNewsAvadel spikes as Oppenheimer says selloff is overdoneN/A
2022-05-26 23:13 ESTNewsAvadel stock falls 26% as FDA cites patent issue in sleep disorder drug FT218 filing; expects tentative approval in 2023N/A
2022-05-26 23:13 ESTNewsJazz Pharmaceuticals benefitting from Avadel's daytime sleepiness drug delayN/A
2022-05-10 00:19 ESTNewsAvadel Pharmaceuticals GAAP EPS of -$0.45 misses by $0.02N/A
2022-05-10 00:19 ESTNewsAvadel Pharmaceuticals plc (AVDL) CEO Gregory Divis on Q1 2022 Results - Earnings Call TranscriptN/A
2022-04-27 02:01 ESTNewsAvadel shares surge as company comments on recent trading activityN/A
2022-04-06 10:44 ESTNewsAvadel reports publication of data showing benefits of sleep disorder drug FT218N/A
2022-03-22 13:38 ESTNewsAvadel Pharmaceuticals Plc: Initiating Buy, Bye Bye To SleepinessN/A
2022-03-18 08:57 ESTNewsAvadel Pharmaceuticals GAAP EPS of -$0.38 beats by $0.03N/A
2022-03-18 08:57 ESTNewsAvadel Pharmaceuticals plc's (AVDL) CEO Gregory Divis on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-12 00:29 ESTNewsAvadel posts new efficacy and safety data for lead candidate in narcolepsyN/A
2021-11-09 01:43 ESTNewsAvadel Pharmaceuticals EPS beats by $0.01N/A
2021-11-09 01:43 ESTNewsAvadel records rising costs in Q3 amid plans to launch narcolepsy therapyN/A
2021-11-09 01:43 ESTNewsAvadel Pharmaceuticals plc (AVDL) CEO Gregory Divis on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-05 19:20 ESTNewsAvadel Pharmaceuticals Q3 2021 Earnings PreviewN/A
2021-11-01 13:34 ESTNewsAvadel Pharmaceuticals: I Am HoldingN/A

About Avadel Pharmaceuticals plc (AVDL):

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. The company's lead product candidate is FT218, a formulation of sodium oxybate which is in a Phase 3 clinical trial for the treatment excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

AVDL Quotes by TradingView

See Advanced Chart

General

  • Name Avadel Pharmaceuticals plc
  • Symbol AVDL
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryDrug Manufacturers-Specialty & Generic
  • Full Time Employees 32
  • Fiscal Year EndDecember
  • IPO Date1996-06-07
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryPharmaceuticals
  • Gic SubIndustryPharmaceuticals
  • Web URLhttp://www.avadel.com
View More

Valuation

  • Trailing PE 71.85
  • Price/Sales (Trailing 12 Mt.) 11.79
  • Price/Book (Most Recent Quarter) 2.73
  • Enterprise Value Revenue 16.33
  • Enterprise Value EBITDA 37.99
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$1.32
  • Next Year EPS Estimate -$0.14
  • Next Quarter EPS Estimate -$0.25
  • Profit Margin 31%
  • Operating Margin -164%
  • Return on Assets -10%
  • Return on Equity 11%
  • Revenue 22.33 million
  • Earnings Per Share $0.13
  • Revenue Per Share $0.42
  • Gross Profit 16.59 million
  • Quarterly Earnings Growth -100%
View More

Highlights

  • Market Capitalization 546.06 million
  • EBITDA -38869000
  • PEG Ratio 0.07
  • Analyst Target Price $18.56
  • Book Value Per Share $2.78
View More

Share Statistics

  • Shares Outstanding 58.47 million
  • Shares Float 42.53 million
  • % Held by Insiders 589%
  • % Held by Institutions 56.94%
  • Shares Short 4.58 million
  • Shares Short Prior Month 3.77 million
  • Short Ratio 6.04
  • Short % of Shares Outstanding 8%
View More

Technicals

  • Beta 1.47
  • 52 Week High $12
  • 52 Week Low $4.83
  • 50 Day Moving Average 8.46
  • 200 Day Moving Average 6.8
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Avadel Pharmaceuticals plc (AVDL) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Avadel Pharmaceuticals plc (AVDL) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-09$N/A-$0.19-$0.2830.91%
2020-09-302020-11-09$N/A-$0.20-$0.2518.37%
2020-06-302020-08-10$N/A$0.49-$0.10578.05%
2020-03-312020-05-11$12.24 million-$0.02-$0.2391.21%
2019-12-312020-03-12$11 million-$0.07-$0.2672.73%
2019-09-302019-11-12$14.23 million-$0.24-$0.2711.11%
2019-06-302019-08-09$17.55 million-$0.23-$0.2920.69%
2019-03-312019-05-08$16.44 million-$0.35-$0.4928.57%
2018-12-312019-03-15$20.92 million-$1.72-$2.3426.5%
2018-09-302018-11-05$19.83 million-$0.43-$0.36-21.13%
2018-06-302018-08-07$29.23 million-$0.09-$0.3271.88%
2018-03-312018-05-02$33.29 million-$0.32-$0.3713.51%
2017-12-312018-03-08$34.41 million-$0.24-$0.3735.14%
2017-09-302017-11-08$39.68 million$0.52-$0.023071.43%
2017-06-302017-08-08$45.21 million$0.68$0.09684.31%
2017-03-312017-05-09$52.51 million$0.59$0.11436.36%
2016-12-312017-03-07$43.09 million$0.11-$0.37129.73%
2016-09-302016-11-07$32.09 million-$0.54-$0.23-134.78%
2016-06-302016-08-08$38.86 million-$0.48$0.06-900%
2016-03-312016-05-09$36.22 million-$0.15$0.14-207.14%
2015-12-312016-03-10$44.57 million$1.75$0.091844.44%
2015-09-302015-11-12$47.31 million-$0.73$0.23-417.39%
2015-06-302015-07-30$48.6 million-$0.43$0.40-207.5%
2015-03-312015-05-15$32.53 million$0.27$0.31-12.9%
2014-12-312015-03-19$2.97 million-$0.69-$0.17-305.88%
2014-09-302014-10-31$2.91 million-$0.26-$0.12-116.67%
2014-06-302014-07-29$4.32 million-$0.13-$0.09-44.44%
2014-03-312014-05-12$4.58 million-$0.60-$0.15-300%
2013-12-312014-03-06$6.18 million$0.20-$0.16225%
2013-09-302013-10-31$5.58 million-$0.25-$0.20-25%
2013-06-302013-07-29$5.54 million-$1.21-$0.27-348.15%
2013-03-312013-05-07$5.14 million-$0.35-$0.33-6.06%
2012-12-312013-02-28$7.31 million$0.46-$0.19342.11%
2012-09-302012-11-05$5.4 million-$0.26-$0.19-36.84%
2012-06-302012-07-25$6.03 million$0.25-$0.08412.5%
2012-03-312012-05-07$7.36 million-$0.19-$0.07-171.43%
2011-12-312012-03-14$8.65 million-$0.08$0.10-180%
2011-09-302011-11-02$10.43 million$0.07-$0.09177.78%
2011-06-302011-07-25$6.75 million-$0.14-$0.09-55.56%
2011-03-312011-05-09$6.76 million-$0.20-$0.11-81.82%
2010-12-312011-03-03$13.45 million$0.11$0.05120%
2010-09-302010-11-04$8.04 million-$0.14
2010-06-302010-07-28$7.52 million-$0.18-$0.05-260%
2010-03-312010-05-05$8.09 million-$0.17-$0.13-30.77%
2009-12-312010-03-08$10.59 million-$0.23-$0.10-130%
2009-09-302009-11-16$9.9 million-$0.14-$0.09-55.56%
2009-06-302009-08-05$9.58 million-$0.15-$0.10-50%
2009-03-312009-05-11$12.05 million$0.05-$0.14135.71%
2008-12-312009-03-04$9.47 million-$0.11-$0.02-450%
2008-09-302008-11-03$9.14 million-$0.10-$0.1741.18%
2008-06-302008-08-06$9.15 million-$0.14-$0.2544%
2008-03-312008-05-13$10.87 million-$0.15-$0.2948.28%
2007-12-312008-03-03$10.56 million-$0.23-$0.3330.3%
2007-09-302007-10-30$9.02 million-$0.38-$0.417.32%
2007-06-302007-08-01$7.45 million-$0.57-$0.28-103.57%
2007-03-312007-05-07$9.63 million-$0.38-$0.33-15.15%
2006-12-312007-03-07$7.78 million-$0.25-$0.3732.43%
2006-09-302006-11-01$5.41 million-$0.43-$0.38-13.16%
2006-06-302006-07-31$4.74 million-$0.40-$0.33-21.21%
2006-03-312006-05-03$5.1 million-$0.41-$0.31-32.26%
2005-12-312006-03-07$6.26 million-$0.28-$0.3417.65%
2005-09-302005-10-26$3.09 million-$0.50-$0.37-35.14%
2005-06-302005-07-27$6.14 million-$0.41-$0.39-5.13%
2005-03-312005-05-05$8.11 million$0.01-$0.03133.33%
2004-12-312005-03-11$18.72 million$0.28$0.31-9.68%
2004-09-302004-10-28$13.35 million$0.12$0.119.09%
2004-06-302004-07-29$8.99 million-$0.07$0.07-200%
2004-03-312004-04-29$14.35 million$0.18$0.03500%
2003-12-312004-03-11$11.27 million$0.08$0.04100%
2003-09-302003-10-30$5.37 million-$0.11$0.05-320%
2003-06-302003-07-30$5 million-$0.10$0.02-600%
2003-03-312003-04-30$3.53 million-$0.10$0.03-433.33%
1998-12-311999-02-23-$0.12-$0.10-20%
1998-09-301998-10-27-$0.17-$0.13-30.77%
1998-06-301998-07-31-$0.22-$0.18-22.22%
1997-12-311998-03-17$0.00-$0.15100%
1997-06-301997-07-31-$0.22-$0.248.33%
1996-12-311997-03-26-$0.15-$0.1816.67%

Avadel Pharmaceuticals plc (AVDL) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Avadel Pharmaceuticals plc (AVDL) Chart:

Avadel Pharmaceuticals plc (AVDL) News:

Below you will find a list of latest news for Avadel Pharmaceuticals plc (AVDL) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Avadel Pharmaceuticals plc (AVDL) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-08-152.50CALL0 0401.88TRUE00
2025-08-1550CALL0 0262.44TRUE00
2025-08-157.53.4CALL230 99784.34TRUE-0.16-0.04
2025-08-15101.3CALL190 174470.69TRUE0.020.02
2025-08-1512.50.3CALL109 20470.4FALSE00
2025-08-15150.01CALL0 14194.8FALSE00
2025-08-1517.50CALL0 0155.83FALSE00
2025-08-152.50PUT0 0475.79FALSE00
2025-08-1550PUT0 0143.68FALSE00
2025-08-157.50.13PUT0 251100.79FALSE00
2025-08-15100.46PUT0 12486.15FALSE00
2025-08-1512.53.3PUT0 4369.13TRUE00
2025-08-15150PUT0 0109.37TRUE00
2025-08-1517.50PUT0 0124.66TRUE00
2025-09-192.50CALL0 0262.38TRUE00
2025-09-1956.03CALL2 14139.09TRUE6.030
2025-09-197.53.1CALL0 7869.56TRUE00
2025-09-19101.6CALL77 88864.04TRUE0.050.03
2025-09-1912.50.43CALL0 40247.41FALSE00
2025-09-19150.1CALL0 41057.58FALSE00
2025-09-1917.50CALL0 0102.26FALSE00
2025-09-19200CALL0 0119.7FALSE00
2025-09-192.50PUT0 0314.8FALSE00
2025-09-1950PUT0 12107.36FALSE00
2025-09-197.50.05PUT0 21762.51FALSE00
2025-09-19100.63PUT1 33359.68FALSE0.630
2025-09-1912.52.45PUT0 559.08TRUE00
2025-09-19150PUT0 052.87TRUE00
2025-09-1917.50PUT0 071.57TRUE00
2025-09-19200PUT0 087.13TRUE00
2025-12-192.50CALL0 0192.82TRUE00
2025-12-1950CALL0 091.73TRUE00
2025-12-197.52.3CALL0 2766.46TRUE00
2025-12-19101.95CALL0 15360.15TRUE00
2025-12-1912.51.1CALL0 17161.87FALSE00
2025-12-19150.5CALL0 96561.38FALSE00
2025-12-1917.50.45CALL3 259.94FALSE0.450
2025-12-19200CALL0 057.48FALSE00
2025-12-192.50PUT0 0201.76FALSE00
2025-12-1950.39PUT0 1113.98FALSE00
2025-12-197.50.8PUT0 3258.78FALSE00
2025-12-19101.5PUT0 1044.35FALSE00
2025-12-1912.53.8PUT0 161.87TRUE00
2025-12-19150PUT0 061.72TRUE00
2025-12-1917.50PUT0 057.08TRUE00
2025-12-19200PUT0 079.52TRUE00
2026-01-162.50CALL0 0135.86TRUE00
2026-01-1655.69CALL0 36794.38TRUE00
2026-01-167.54.1CALL80 60874.53TRUE4.10
2026-01-16102.52CALL190 1167768.22TRUE-0.07-0.03
2026-01-1612.51.07CALL0 100656.52FALSE00
2026-01-16150.9CALL1 301066.36FALSE0.090.11
2026-01-1617.50.33CALL0 190353.52FALSE00
2026-01-16200.3CALL0 36256.72FALSE00
2026-01-1622.50.1CALL0 13457.62FALSE00
2026-01-16250.05CALL1 6256.94FALSE0.050
2026-01-16300CALL0 3497.02FALSE00
2026-01-16350CALL0 1106.76FALSE00
2026-01-162.50PUT0 0185.82FALSE00
2026-01-1650PUT0 12113.99FALSE00
2026-01-167.50.74PUT0 86666.65FALSE00
2026-01-16101.63PUT0 88576.6FALSE00
2026-01-1612.52.85PUT0 27663.31TRUE00
2026-01-16154.6PUT0 100861.55TRUE00
2026-01-1617.56.9PUT0 15072.36TRUE00
2026-01-16200PUT0 071.51TRUE00
2026-01-1622.50PUT0 084.2TRUE00
2026-01-16250PUT0 0108.09TRUE00
2026-01-16300PUT0 0123.19TRUE00
2026-01-16350PUT0 0101.32TRUE00
2026-03-202.50CALL0 098.83TRUE00
2026-03-2050CALL0 078.51TRUE00
2026-03-207.50CALL0 067.13TRUE00
2026-03-20100CALL0 046.73TRUE00
2026-03-2012.50CALL0 065.6FALSE00
2026-03-20150CALL0 050.22FALSE00
2026-03-2017.50CALL0 051.13FALSE00
2026-03-20200CALL0 057.82FALSE00
2026-03-202.50PUT0 0174.42FALSE00
2026-03-2050PUT0 070.1FALSE00
2026-03-207.50PUT0 066.46FALSE00
2026-03-20100PUT0 062.26FALSE00
2026-03-2012.50PUT0 058.7TRUE00
2026-03-20150PUT0 062.77TRUE00
2026-03-2017.50PUT0 068.14TRUE00
2026-03-20200PUT0 064.28TRUE00
2027-01-152.50CALL0 059.25TRUE00
2027-01-1555CALL0 53965.85TRUE00
2027-01-157.54.39CALL0 41487.95TRUE00
2027-01-15103CALL0 43258.75TRUE00
2027-01-1512.52.74CALL0 11758.81FALSE00
2027-01-15152CALL0 18957.73FALSE00
2027-01-1517.50CALL0 555.23FALSE00
2027-01-15201.05CALL0 6245.42FALSE00
2027-01-1522.50.9CALL2 3956.8FALSE0.90
2027-01-15250.65CALL0 2448.17FALSE00
2027-01-15300CALL0 050.66FALSE00
2027-01-152.50PUT0 0138.76FALSE00
2027-01-1550PUT0 474.26FALSE00
2027-01-157.50PUT0 1159.42FALSE00
2027-01-15100PUT0 350.3FALSE00
2027-01-1512.50PUT0 366.2TRUE00
2027-01-15150PUT0 056.52TRUE00
2027-01-1517.58.44PUT0 157.73TRUE00
2027-01-15200PUT0 053.97TRUE00
2027-01-1522.50PUT0 054.13TRUE00
2027-01-15250PUT0 059.84TRUE00
2027-01-15300PUT0 087.29TRUE00

Latest AVDL Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST300$2.245
Jun 13, 2022 7:59 PM EST360$2.245
Jun 13, 2022 7:59 PM EST140$2.245
Jun 13, 2022 7:59 PM EST634$2.245
Jun 13, 2022 7:59 PM EST2$2.25

Avadel Pharmaceuticals plc (AVDL) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465920080648/0001104659-20-080648-index.htm
2020-02-12UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1012477/000000000020001346/0000000000-20-001346-index.htm
2020-05-08UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1012477/000000000020004060/0000000000-20-004060-index.htm
2019-11-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000091068019000084/0000910680-19-000084-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1012477/000091957420001139/0000919574-20-001139-index.htm
2019-11-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1012477/000101247719000012/0001012477-19-000012-index.htm
2020-03-1610-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1012477/000101247720000007/0001012477-20-000007-index.htm
2020-05-1110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1012477/000101247720000009/0001012477-20-000009-index.htm
2020-08-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1012477/000101247720000013/0001012477-20-000013-index.htm
2019-11-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465919062085/0001104659-19-062085-index.htm
2019-11-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465919066833/0001104659-19-066833-index.htm
2019-12-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465919068803/0001104659-19-068803-index.htm
2019-12-033Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000110465919069621/0001104659-19-069621-index.htm
2019-12-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000110465919069622/0001104659-19-069622-index.htm
2019-12-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465919070110/0001104659-19-070110-index.htm
2019-12-05SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1012477/000110465919070118/0001104659-19-070118-index.htm
2019-12-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000110465919070213/0001104659-19-070213-index.htm
2019-12-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000110465919070217/0001104659-19-070217-index.htm
2019-12-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465919071189/0001104659-19-071189-index.htm
2019-12-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465919072792/0001104659-19-072792-index.htm
2019-12-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465919073238/0001104659-19-073238-index.htm
2020-01-07SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1012477/000110465920001912/0001104659-20-001912-index.htm
2020-01-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465920003111/0001104659-20-003111-index.htm
2020-02-05S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1012477/000110465920010987/0001104659-20-010987-index.htm
2020-02-13CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1012477/000110465920020153/0001104659-20-020153-index.htm
2020-02-13CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1012477/000110465920020407/0001104659-20-020407-index.htm
2020-02-13CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1012477/000110465920020410/0001104659-20-020410-index.htm
2020-02-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465920024077/0001104659-20-024077-index.htm
2020-03-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465920032146/0001104659-20-032146-index.htm
2020-03-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465920037990/0001104659-20-037990-index.htm
2020-04-16PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1012477/000110465920047632/0001104659-20-047632-index.htm
2020-04-27DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1012477/000110465920051182/0001104659-20-051182-index.htm
2020-04-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465920051350/0001104659-20-051350-index.htm
2020-04-28424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1012477/000110465920051827/0001104659-20-051827-index.htm
2020-04-29424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1012477/000110465920053562/0001104659-20-053562-index.htm
2020-04-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465920053569/0001104659-20-053569-index.htm
2020-05-01S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1012477/000110465920055587/0001104659-20-055587-index.htm
2020-05-08CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1012477/000110465920058802/0001104659-20-058802-index.htm
2020-05-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465920059095/0001104659-20-059095-index.htm
2020-06-16DEFR14ARevised definitive proxy soliciting materialshttps://www.sec.gov/Archives/edgar/data/1012477/000110465920073527/0001104659-20-073527-index.htm
2020-06-24424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1012477/000110465920076183/0001104659-20-076183-index.htm
2020-07-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465920080648/0001104659-20-080648-index.htm
2020-07-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465920082927/0001104659-20-082927-index.htm
2020-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465920091513/0001104659-20-091513-index.htm
2020-08-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465920092424/0001104659-20-092424-index.htm
2020-08-208-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465920097315/0001104659-20-097315-index.htm
2020-08-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465920100190/0001104659-20-100190-index.htm
2020-09-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465920104616/0001104659-20-104616-index.htm
2019-12-093Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911019012565/0001179110-19-012565-index.htm
2019-12-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911019012567/0001179110-19-012567-index.htm
2019-12-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911019012826/0001179110-19-012826-index.htm
2020-08-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020008889/0001179110-20-008889-index.htm
2020-08-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020008890/0001179110-20-008890-index.htm
2020-08-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020008891/0001179110-20-008891-index.htm
2020-08-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020008892/0001179110-20-008892-index.htm
2020-08-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020008893/0001179110-20-008893-index.htm
2020-08-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020009023/0001179110-20-009023-index.htm
2020-08-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020009024/0001179110-20-009024-index.htm
2020-08-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020009054/0001179110-20-009054-index.htm
2020-08-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020009083/0001179110-20-009083-index.htm
2020-08-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020009084/0001179110-20-009084-index.htm
2020-08-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020009086/0001179110-20-009086-index.htm
2020-09-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020009461/0001179110-20-009461-index.htm
2020-09-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020009462/0001179110-20-009462-index.htm
2020-09-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020009709/0001179110-20-009709-index.htm
2020-09-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020009877/0001179110-20-009877-index.htm
2020-09-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020009879/0001179110-20-009879-index.htm
2020-09-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020009897/0001179110-20-009897-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1012477/000119380520000194/0001193805-20-000194-index.htm
2020-03-04SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1012477/000121390020005412/0001213900-20-005412-index.htm
2019-12-30SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1012477/000149315219019859/0001493152-19-019859-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1012477/000149315220002411/0001493152-20-002411-index.htm
2019-11-143Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000156761919021621/0001567619-19-021621-index.htm
2019-11-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000156761919021625/0001567619-19-021625-index.htm
2019-11-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000156761919021875/0001567619-19-021875-index.htm
2019-11-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000156761919021885/0001567619-19-021885-index.htm
2019-11-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000156761919021887/0001567619-19-021887-index.htm
2020-02-14EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1012477/999999999520000371/9999999995-20-000371-index.htm
2020-05-12EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1012477/999999999520001129/9999999995-20-001129-index.htm

Avadel Pharmaceuticals plc (AVDL) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Avadel Pharmaceuticals plc (AVDL). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 589%
Institutional Ownership: 5694%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-08-13THOMAS S MCHUGHChief Financial OfficerBuy10,000.007.7877,814.0010,000.00https://www.sec.gov/Archives/edgar/data/1012477/000117911020009086/0001179110-20-009086-index.htm
2020-09-16Mark Anthony McCamishDirectorBuy118,602.005.73679,968.99118,602.00https://www.sec.gov/Archives/edgar/data/1012477/000117911020009879/0001179110-20-009879-index.htm
2020-09-17Mark Anthony McCamishDirectorBuy52,398.005.83305,249.79171,000.00https://www.sec.gov/Archives/edgar/data/1012477/000117911020009879/0001179110-20-009879-index.htm
2020-08-28THOMAS S MCHUGHChief Financial OfficerBuy7,500.006.7750,776.5017,500.00https://www.sec.gov/Archives/edgar/data/1012477/000117911020009462/0001179110-20-009462-index.htm
2020-09-18THOMAS S MCHUGHChief Financial OfficerBuy4,000.006.0024,000.0021,500.00https://www.sec.gov/Archives/edgar/data/1012477/000117911020009897/0001179110-20-009897-index.htm
2019-11-15Geoffrey Michael GlassDirectorBuy5,000.004.9924,950.0032,900.00https://www.sec.gov/Archives/edgar/data/1012477/000156761919021887/0001567619-19-021887-index.htm
2019-12-03Linda PalczukDirectorBuy7,500.005.9144,325.0035,400.00https://www.sec.gov/Archives/edgar/data/1012477/000110465919070213/0001104659-19-070213-index.htm
2019-11-15Eric J EndeDirectorBuy10,000.004.9849,762.0037,900.00https://www.sec.gov/Archives/edgar/data/1012477/000156761919021875/0001567619-19-021875-index.htm
2020-08-14Linda PalczukDirectorBuy2,500.007.9419,849.7537,900.00https://www.sec.gov/Archives/edgar/data/1012477/000117911020009084/0001179110-20-009084-index.htm
2019-12-04Eric J EndeDirectorBuy10,000.005.9759,700.0047,900.00https://www.sec.gov/Archives/edgar/data/1012477/000110465919070217/0001104659-19-070217-index.htm
2019-11-18Geoffrey Michael GlassDirectorBuy15,000.004.9974,850.0047,900.00https://www.sec.gov/Archives/edgar/data/1012477/000156761919021887/0001567619-19-021887-index.htm
2020-08-12Geoffrey Michael GlassDirectorBuy6,500.007.7050,050.0054,400.00https://www.sec.gov/Archives/edgar/data/1012477/000117911020009054/0001179110-20-009054-index.htm
2019-12-12Sandra L HattenOfficerSell3,072.007.2322,210.5655,765.00https://www.sec.gov/Archives/edgar/data/1012477/000117911019012826/0001179110-19-012826-index.htm
2020-08-13Geoffrey Michael GlassDirectorBuy6,500.007.7650,440.0060,900.00https://www.sec.gov/Archives/edgar/data/1012477/000117911020009054/0001179110-20-009054-index.htm
2020-08-12Eric J EndeDirectorBuy15,000.007.76116,355.0062,900.00https://www.sec.gov/Archives/edgar/data/1012477/000117911020009024/0001179110-20-009024-index.htm
2020-08-13Eric J EndeDirectorBuy1,200.007.749,288.0064,100.00https://www.sec.gov/Archives/edgar/data/1012477/000117911020009083/0001179110-20-009083-index.htm
2020-08-28Geoffrey Michael GlassDirectorBuy4,800.006.7832,559.8465,700.00https://www.sec.gov/Archives/edgar/data/1012477/000117911020009461/0001179110-20-009461-index.htm
2020-08-13Eric J EndeDirectorBuy3,800.007.8029,640.0067,900.00https://www.sec.gov/Archives/edgar/data/1012477/000117911020009083/0001179110-20-009083-index.htm
2020-09-17Eric J EndeDirectorBuy17,000.005.7998,375.6084,900.00https://www.sec.gov/Archives/edgar/data/1012477/000117911020009877/0001179110-20-009877-index.htm
2019-11-15GREG J DIVISChief Executive OfficerBuy19,000.005.1397,470.0086,100.00https://www.sec.gov/Archives/edgar/data/1012477/000156761919021885/0001567619-19-021885-index.htm
2020-08-12Gregory J DivisChief Executive OfficerBuy13,000.007.78101,155.6099,100.00https://www.sec.gov/Archives/edgar/data/1012477/000117911020009023/0001179110-20-009023-index.htm